Drugs / MIS416
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01191996 | Aug 2010 → Jun 2012 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Innate Immunotherapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02228213 | Oct 2014 → May 2017 | secondary progressive multiple sclerosis | Innate Immunotherapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIS416 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02228213 ↗ |
| Route | Intravenous | “MIS416 administered IV once weekly” NCT01191996 ↗ |